Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema (Q24202071)

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

The pathogenesis of edema in diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Risk factors for diffuse and focal macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Current approaches to the management of diabetic retinopathy and diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Diabetic maculopathy. A critical review highlighting diffuse macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Corticosteroids in posterior segment disease: an update on new delivery systems and new indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal steroids for macular edema in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Health utility values associated with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A review of clinical trials of anti-VEGF agents for diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Interventions for diabetic macular oedema: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Review of guidelines for good practice in decision-analytic modelling in health technology assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Anti-vascular endothelial growth factor agents for diabetic maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Relative cost of a line of vision in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Economic Considerations of Macular Edema Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Epidemiology of diabetic retinopathy and macular oedema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

Abnormalities of the foveal avascular zone in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

The role of capillary perfusion in the management of diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

The evidence provided by a single trial is less reliable than its statistical analysis suggests

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Angiogenic pathways in diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

1 reference

7 January 2021

Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Valuing Condition-Specific Health States Using Simulation Contact Lenses

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Why using Avastin for eye disease is so difficult

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021

Diabetic macular edema

1 reference

https://api.crossref.org/works/10.1002/14651858.CD007419.PUB3

7 January 2021